Active Ingredient History

  • Now
Pomaglumetad (LY-404,039) is an amino acid analog drug that acts as a highly selective agonist for the metabotropic glutamate receptor group II subtypes mGluR2 and mGluR3. Pharmacological research has focused on its potential antipsychotic and anxiolytic effects. Pomaglumetad is intended as a treatment for schizophrenia and other psychotic and anxiety disorders by modulating glutamatergic activity and reducing presynaptic release of glutamate at synapses in limbic and forebrain areas relevant to these disorders. Human studies investigating therapeutic use of pomaglumetad have focused on the prodrug LY-2140023, a methionine amide of pomaglumetad (also called pomaglumetad methionil) since pomaglumetad exhibits low oral absorption and bioavailability in humans.   Wikipedia

  • SMILES: CSCC[C@H](N)C(=O)N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(=O)O)C(=O)O
  • Mol. Mass: 366.42
  • ALogP: -1.87
  • ChEMBL Molecule:
More Chemistry
ly2140023 | ly 2140023 | ly-2140023 | ly2140023 monohydrate | pomaglumetad | pomaglumetad methionil


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue